Express Scripts moving to performance-based contracts with drug industry, out of carve-outs, exec says.
Executive Summary
EXPRESS SCRIPTS SEES MOVE AWAY FROM "ERA OF DISCOUNTING," anticipating more performance-based contracts with the pharmaceutical sector over the next three years, CEO Barrett Toan told analysts at the Alex. Brown health care seminar. The independent PBM covering approximately 9 mil. lives "will be increasingly involved in strategic relationships with the pharmaceutical manufacturing sector" in terms of pharmacy services, Toan said.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth